Mineralys Therapeutics (MLYS) Return on Equity [ROE] (2023 - 2026)
Mineralys Therapeutics' Return on Equity [ROE] was -73.38% in Q3 2026, down 32.96 percentage points from -40.43% a year earlier and down 11.72 percentage points from the prior quarter.
Powered by 
Analysis
Mineralys Therapeutics (MLYS) Return on Equity [ROE] (2023 - 2026) Analysis & Trends
For FY2025, Return on Equity [ROE] at Mineralys Therapeutics came in at -40.72%, up 48.27 percentage points from FY2024.
- In earlier years, Return on Equity [ROE] was -88.99% in FY2024 (+0.65 pp) and -89.64% in FY2023.
- The Q3 2026 figure marks the lowest quarterly Return on Equity [ROE] since Q1 2025.
- Compared with a year earlier, Return on Equity [ROE] was higher in four of the last eight quarters, with an average year-over-year change of -1.31 percentage points.
- The best year-over-year quarter for Return on Equity [ROE] over five years was Q4 2025 (a gain of 62.66 percentage points); the worst was Q4 2024 (a drop of 56.35 percentage points).
- Per Business Quant data, MLYS's Return on Equity [ROE] in the three quarters before Q3 2026 was -61.66% (Q2 2026), -26.04% (Q1 2026) and -27.21% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 74.39% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | - |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.63% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 21.60% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 72.13% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -31.17% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 4.66% |
| 10 | Mineralys Therapeutics | 1.37 Bn | -1.21 Bn | - | -73.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -73.38% |
| Jun 30, 2026 | -61.66% |
| Mar 31, 2026 | -26.04% |
| Dec 31, 2025 | -27.21% |
| Sep 30, 2025 | -40.43% |
| Jun 30, 2025 | -61.99% |
| Mar 31, 2025 | -75.63% |
| Dec 31, 2024 | -89.87% |
| Sep 30, 2024 | -63.89% |
| Jun 30, 2024 | -43.52% |
| Mar 31, 2024 | -36.92% |
| Dec 31, 2023 | -33.52% |
| Sep 30, 2023 | -24.39% |
| Jun 30, 2023 | -16.56% |
| Mar 31, 2023 | -31.89% |
API Access
Mineralys Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MLYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "MLYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MLYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();